Two-year real-world data highlight strong drug survival and effectiveness of bimekizumab in plaque psoriasis. Learn more ...

Nearly 9 in 10 adults and parents of children with plaque psoriasis, atopic dermatitis, and seborrheic dermatitis being ...

Reader's DigestHome Remedies for Eczema and Psoriasis ReliefSave money on expensive skin care treatments and try these homemade remedies first. Plaque psoriasis is a skin disease that causes raised ...

84% of adolescents with moderate-to-severe plaque psoriasis treated with investigational icotrokinra achieved clear or almost clear skin (IGA 0/1) at Week 16 ICONIC-LEAD is the first ever Phase 3 ...

Alumis (ALMS) shares climbed nearly 150% on Tuesday after the autoimmune disease drug developer said its lead candidate, envudeucitinib, reached the main goals in two Phase 3 trials for a skin ...

Since revealing her plaque psoriasis diagnosis in 2015, La La Anthony has become a powerful voice for those living with the chronic skin condition. Plaque psoriasis—often mistaken for dry skin or ...

Shares of Alumis ALMS surged 95.3% on Jan. 6, after the company announced positive top-line data from its two phase III studies — ONWARD1 and ONWARD2 — which evaluated its pipeline candidate, ...

Takeda’s zasocitinib has shown strong rates of skin clearance, as well as other benefits, in new study results regarding ...

Alisha Bridges, 36, knows what it feels like to be treated differently because of how she looks. Since elementary school, Alisha has struggled with severe plaque psoriasis—a condition which causes ...

ICONIC-LEAD is the first ever Phase 3 registrational study in moderate-to-severe plaque psoriasis to assess safety and efficacy of a systemic therapy in adolescents and adults simultaneously 84% of ...